top of page

Impairment Science Announces “DRUID RESEARCH” for Scientific Researchers

DRUID RESEARCH retains the precise measures regardless of required app upgrades

EMS Services recruits in fitness training

DRUID is setting a new standard for the detection and measurement of cognitive impairment by the scientific community.

 

More than a dozen scientific researchers at major academic institutions have now licensed Impairment Science’s DRUID app for their own research into cognitive impairment, whether from alcohol, drugs (including cannabis), fatigue, aging, or other causes. Impairment Science has now developed a new version of its impairment test “DRUID RESEARCH” that retains the precise measures required to maintain a reliable, unaltered test over time as Google and Apple upgrade their operating systems.

 

The research community has been a vital part of Impairment Science’s growth since the company’s inception. An SBIR grant funded by the National Institutes of Health in 2019, used to validate DRUID’s accuracy, has led to research institutions selecting DRUID for their clinical studies.

 

“We recognize the importance of a fast, reliable, accurate, cognitive testing tool for scientific research and developed a solution that accommodates the needs of longitudinal studies,” said CEO Rob Schiller. “To comply with regular updates required by Apple and Google operating systems, we created DRUID RESEARCH to freeze the test experience so our researchers can rely on a consistent set of measures.”

 

DRUID RESEARCH will support the growing number of vital academic studies analyzing a broad array of causes of impairment. Dr. Ryan Vandrey of the Johns Hopkins School of Medicine Faculty is leading a study that will be the first to deploy the new version. This longitudinal study will span 5 years with participants from all over the country taking DRUID tests on a mix of Apple and Android devices before and after cannabis consumption. As noted in its abstract, this study “will help inform clinical decision-making about the medicinal use of cannabis as well as help steer policy and regulatory decisions in the interest of public and patient health.”

 

For more information about the DRUID RESEARCH, contact Rob Schiller.






41 views

Comentarios


bottom of page